Review
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9512-9525
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9512
Figure 5
Figure 5 Results of a randomized controlled trial of Sunitinib vs placebo for well-differentiated pancreatic neuroendocrine tumors demonstrating (A) progression free survival and (B) overall survival. From: Raymond et al[98]. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 501-513.